VINCIT: A virus-incorporated biomaterial niche enables spatially controlled in vivo CAR T cell engineering

In vivo generation of chimeric antigen receptor (CAR) T cells could bypass the complex manufacturing required for conventional cell therapies, but systemic gene delivery remains limited by off target exposure and inefficient access to target immune cells. Here, we develop VINCIT (Virus Incorporated Niche for Cellular ImmunoTherapy), an injectable nanofiber hydrogel composite that establishes a localized immune-engineering niche for CAR T cell generation in vivo. VINCIT spatially retains viral vectors while recruiting endogenous immune cells, enabling local transduction of T cells, after which the engineered T cells enter the circulation. VINCIT spatially confines transgene expression compared with intravenous viral delivery and markedly enhances T cell transduction compared with subcutaneously injected free virus. VINCIT is compatible with both adeno-associated and lentiviral vectors, and CAR T cells generated in vivo exhibit antigen-specific effector responses and mediate CD19+ B cell depletion. In a humanized mouse model of lymphoma, a single VINCIT administration produces sustained tumor control and extends median survival from 32 to 110 days. Mechanistically, efficient CAR T cell generation requires coordinated interactions among multiple immune populations, with neutrophil depletion markedly reducing cellular recruitment and subsequent T cell programming. These findings establish a localized biomaterial niche for spatially controlled in vivo immune cell engineering.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.767176
Primary Topic
CAR-T cell therapy research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

VINCIT: A virus-incorporated biomaterial niche enables spatially controlled in vivo CAR T cell engineering

Christine Wei, Yining Zhu, Hai‐Quan Mao, Autumn H. Greco et al.
3 links
bioRxiv (Cold Spring Harbor Laboratory)
CAR-T cell therapy research
preprint

VINCIT: A virus-incorporated biomaterial niche enables spatially controlled in vivo CAR T cell engineering

Christine Wei, Yining Zhu, Hai‐Quan Mao, Autumn H. Greco, Yunhe Su, Maximilian F. Konig, Jiayuan Kong, Jonathan P. Schneck, Joseph Choy, Joshua C. Doloff, Jingyao Ma, Kailei D. Goodier, YIli Jiang, Sabrina Chen, Zhuoqing Jiang, Dylan Luong, Evan Wang, Jinghan Lin, Xiang Liu, Di Yu, D Scott Wilson, Xiaoya Lu
preprint en

Abstract

In vivo generation of chimeric antigen receptor (CAR) T cells could bypass the complex manufacturing required for conventional cell therapies, but systemic gene delivery remains limited by off target exposure and inefficient access to target immune cells. Here, we develop VINCIT (Virus Incorporated Niche for Cellular ImmunoTherapy), an injectable nanofiber hydrogel composite that establishes a localized immune-engineering niche for CAR T cell generation in vivo. VINCIT spatially retains viral vectors while recruiting endogenous immune cells, enabling local transduction of T cells, after which the engineered T cells enter the circulation. VINCIT spatially confines transgene expression compared with intravenous viral delivery and markedly enhances T cell transduction compared with subcutaneously injected free virus. VINCIT is compatible with both adeno-associated and lentiviral vectors, and CAR T cells generated in vivo exhibit antigen-specific effector responses and mediate CD19+ B cell depletion. In a humanized mouse model of lymphoma, a single VINCIT administration produces sustained tumor control and extends median survival from 32 to 110 days. Mechanistically, efficient CAR T cell generation requires coordinated interactions among multiple immune populations, with neutrophil depletion markedly reducing cellular recruitment and subsequent T cell programming. These findings establish a localized biomaterial niche for spatially controlled in vivo immune cell engineering.

bioRxiv (Cold Spring Harbor Laboratory)
Johns Hopkins University (US)
National Institutes of Health, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon